Erytech Pharma (NASDAQ:ERYP) Getting Somewhat Favorable Media Coverage, Analysis Finds
News stories about Erytech Pharma (NASDAQ:ERYP) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Erytech Pharma earned a news impact score of 0.07 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.0694119737366 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Erytech Pharma (ERYP) opened at $23.28 on Tuesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 10.67 and a quick ratio of 10.65. Erytech Pharma has a 1-year low of $17.50 and a 1-year high of $30.56.
ERYP has been the topic of a number of research reports. Cowen initiated coverage on shares of Erytech Pharma in a research note on Tuesday, December 5th. They issued an “outperform” rating on the stock. JMP Securities initiated coverage on shares of Erytech Pharma in a research note on Friday, December 1st. They issued an “outperform” rating and a $43.00 price objective on the stock.
About Erytech Pharma
Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells.
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.